A clear choice for demonstrated high clinical cure rates for
AOMT caused by susceptible isolates of certain microorganisms1,2

Number One Icon

CIPRODEX® Otic is the #1 prescribed antibiotic ear drop of ENTs and pediatricians3

CIPRODEX® Otic was studied in a clinical trial of patients with acute otitis media with tympanostomy tubes (AOMT)1

Plus Icon

Study design

Clinical cure rates in per-protocol–evaluable patients2,4*

Per-protocol patients include all subjects who received the drug and complied with the protocol, including subjects who discontinued the study due to treatment failures.

AOMT Trial

Demonstrated clinical cures noninferior to comparator

Clinical Cure Rates in Per-Protocol—evaluable patients in an AOMT trial

*The primary outcome measure for the demonstration of noninferiority was clinical response
in the per-protocol population at the test of cure visit on Day 18.2

CIPRODEX® Otic

Ofloxacin

Clinical cure rates in culture-positive patients2,4

AOMT Trial

Demonstrated clinical cures noninferior to comparator

Clinical Cure Rates in Culture-Positive patients in an AOMT trial

CIPRODEX® Otic

Ofloxacin

Microbiological eradication rates in
culture-positive patients2,4

AOMT Trial

Demonstrated clinical cures noninferior to comparator

Microbiological Eradication Rates in culture-positive patients in an AOMT trial

CIPRODEX® Otic

Ofloxacin

Resolution of otorrhea2†

Noninferior to comparator

Resolution of Otorrhea in an AOMT trial

The secondary outcome measure was duration to resolution of otorrhea in the per-protocol population.2

CIPRODEX® Otic

Ofloxacin

Learn about the safety profile
Aiden Image

Not an actual patient.

The average out-of-pocket cost for CIPRODEX® Otic is $34

Eligible, commercially insured patients may pay as little as $30 for their prescription with the CIPRODEX® Otic co-pay card.

Help your patients save

Terms and Conditions: Valid only for those with commercial insurance. Offer not valid under Medicare, Medicaid, or any other federal or state program, for cash-paying patients, or where plan reimburses you for the entire cost of your prescription drug. Eligible, commercially insured patients may pay as little as $30 in out-of-pocket expenses for each 7.5mL bottle of CIPRODEX® (ciprofloxacin 0.3% and dexamethasone 0.1%) Sterile Otic Suspension with a maximum benefit per bottle of $170. Offer good for up to three (3) 7.5mL bottles of CIPRODEX® Otic for a single patient. If insured patient reaches maximum benefit per bottle, patient will be responsible for the difference. Offer is not valid where prohibited by law. Valid only in the US, USVI, Guam and Puerto Rico. This program is only valid for those patients 6 months and older. This program is not health insurance. Offer may not be combined with any other rebate, coupon, or offer. This card is the property of Novartis Pharmaceuticals Corporation and must be returned upon request. Novartis reserves the right to rescind, revoke, or amend the program without notice. Patient certifies responsibility for complying with applicable limitations, if any, of any commercial insurance and reporting receipt of program rewards, if necessary, to any commercial insurer.

Plus Icon Plus Icon

INDICATIONS AND IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: CIPRODEX® Otic should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones.

Potential for Microbial Overgrowth with Prolonged Use: Prolonged use of CIPRODEX® Otic may result in overgrowth of non-susceptible bacteria and fungi. If the infection is not improved after one week of treatment, cultures should be obtained to guide further treatment. If such infections occur, discontinue use and institute alternative therapy.

Continued or Recurrent Otorrhea: If otorrhea persists after a full course of therapy, or if two or more episodes occur within six months, further evaluation is recommended to exclude an underlying condition such as cholesteatoma, foreign body, or a tumor.

ADVERSE REACTIONS

The most commonly reported adverse reactions in clinical trials were:

INDICATIONS and USAGE

CIPRODEX® Otic is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in:

DOSAGE

For additional information on CIPRODEX® Otic, please click here for the full Prescribing Information.

References: 1. CIPRODEX [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2015. 2. Smith T. Center for Drug Evaluation and Research (CDER). Medical Officer's Review of NDA 21-537 Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021537_Ciprodex_medr.PDF. Submitted August 7, 2003. Accessed July 12, 2018. 3. IQVIA. CIPRODEX®: Annual TRx & NRx Q3 2018. Novartis Pharmaceuticals Corp; September 2018. 4. Data on file. Novartis Pharmaceuticals Corp.